Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH‐EXAMINER as a potential clinical trial endpoint

Abstract

Identifying clinical measures that track disease in the earliest stages of frontotemporal lobar degeneration (FTLD) is important for clinical trials. Familial FTLD provides a unique paradigm to study early FTLD. Executive dysfunction is a clinically relevant hallmark of FTLD and may be a marker of disease progression.

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 01, 2020
Source ID
10.1016/j.jalz.2019.01.012

Entities

People

  • Adam L. Boxer
  • Adam M. Staffaroni
  • Alex Pantelyat
  • Amy Wolf
  • Ann Fishman
  • Anna Karydas
  • Arthur W. Toga
  • Behnaz Ghazanfari
  • Bonnie Wong
  • Brad F. Boeve
  • Bradford C. Dickerson
  • Brian Appleby
  • Bruce L. Miller
  • Chiadi Onyike
  • Christina Caso
  • Christina Dheel
  • Codrin Lungu
  • Dana Haley
  • Daniel I. Kaufer
  • Danielle Brushaber
  • David J. Irwin
  • David S. Knopman
  • David T. Jones
  • Debra Gearhart
  • Diana R. Kerwin
  • Diane Lucente
  • Edward D. Huey
  • Eliana Marisa Ramos
  • Emily Mckinley
  • Emily Rogalski
  • Erik D. Roberson
  • Fanny M. Elahi
  • Ging‐yuek Hsiung
  • Giovanni Coppola
  • Hilary W. Heuer
  • Howard J. Rosen
  • Ian Grant
  • Ian R. Mackenzie
  • Irene Litvan
  • Jamie Fong
  • Jaya Padmanabhan
  • Jeremy Syrjanen
  • Jessica Bove
  • Jessica Ferrall
  • Jill Goldman
  • Joanne Taylor
  • Joel H. Kramer
  • John Kornak
  • John Q. Trojanowski
  • Jonathan Graff‐radford
  • Julie A. Fields
  • Katherine P. Rankin
  • Katya Rascovsky
  • Kejal Kantarci
  • Kelly Faber
  • Kimiko Domoto‐reilly
  • Leah K. Forsberg
  • Len Petrucelli
  • Leslie M. Shaw
  • Lynn Bajorek
  • Lynne Jones
  • M. Carmela Tartaglia
  • Madeline Potter
  • Mario F. Mendez
  • Masood Manoochehri
  • Miranda Maldonado
  • Murray Grossman
  • Nadine Tatton
  • Namita Multani
  • Neill Graff‐radford
  • Nupur Ghoshal
  • On Behalf Of The Artfl/lefftds Consortium
  • Patrick Brannelly
  • Peter A. Ljubenkov
  • Pheth Sengdy
  • Ping Wang
  • Ralitza Gavrilova
  • Reilly Dever
  • Rodney Pearlman
  • Rosa Rademakers
  • Ruth Kraft
  • Sandra Weintraub
  • Scott M. Mcginnis
  • Sheng‐yang M. Goh
  • Sophia Dominguez
  • Susan Dickinson
  • Tatiana Foroud
  • Vahan Aslanyan
  • Walter A. Kukull
  • Walter K. Kremers
  • Yann Cobigo
  • Yvette Bordelon
  • Zbigniew K Wszolek

Organizations

  • AbbVie
  • Allergan, Inc.
  • Alzheimer Society of B.C.
  • Alzheimer's Association
  • Alzheimer's Drug Discovery Foundation
  • Association for Frontotemporal Degeneration
  • AstraZeneca
  • Biogen
  • BrightFocus Foundation
  • Bristol-Myers Squibb
  • Canadian Institutes of Health Research
  • Centers for Disease Control and Prevention
  • Eisai
  • GE HealthCare
  • Hoffmann-La Roche
  • Huntington's Disease Society of America
  • Janssen Pharmaceuticals
  • Larry L. Hillblom Foundation
  • Merck & Co.
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging
  • National Institutes of Health
  • New York State Department of Health
  • Pfizer
  • Roche (United States)
  • Swedish Parkinson’s Disease Association
  • The Michael J. Fox Foundation
  • United States Department of Defense
  • University of Southern California
  • Wyeth

Tags

Fields of Study

  • Medicine

Readers

  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.
  • Psychological Intervention/Treatment for Stress, Anxiety, PTSD, and Related Emotional and Cognitive Health Symptoms.
  • Traumatic Brain Injury (TBI) and Cognitive Aging in the Guam and Border Populations Affected by Alzheimer's Disease and Tau-Associated Dementias.